Decentralised Trials in APAC: Why the Frontier Hasn't Arrived — and What It Will Take

Ask clinical-operations leaders across Asia-Pacific whether decentralised and hybrid trials are the future, and the answer is almost unanimous. At West China Hospital — one of Asia's largest trial centres — an IQVIA查看公司主页 survey found that roughly nine in ten participants regarded decentralised participation as an acceptable way to take part in research. Industry analysts project that the global market for decentralised clinical trials (DCTs) will more than double, from around USD 9 billion in 2025 toward USD 21 billion by the early 2030s, with Asia-Pacific the fastest-growing region of all. By any reading of stated intent, the frontier should already be here.

And yet, on the ground, it is not. Despite the optimism, the published frameworks and the pilot programmes, decentralised and hybrid trials have not scaled across APAC at anything like the pace the enthusiasm implies. The dominant 2025 reality is not the fully remote trial of the conference keynote; it is selective decentralisation — a remote follow-up here, a local lab draw there, eConsent bolted onto an otherwise conventional protocol. The frontier keeps arriving in fragments.

The gap nobody planned for

The enthusiasm is real and measurable. IQVIA查看公司主页's site survey across Asia-Pacific captured broad optimism among investigators and coordinators, who pointed to lower patient burden, better trial continuity and more inclusive recruitment as the tangible benefits of hybrid designs. Speaking to BioPharma APAC, IQVIA's regional clinical-development and DCT-deployment leads framed APAC as a prime location for trials precisely because of its large, ethnically diverse patient pool — while cautioning that the region is not one market but many, spanning healthcare systems of wildly different maturity, funding and digital readiness.

The disappointment lives in the conversion. High stated interest has translated into modest, piecemeal adoption: hybrid pilots that prove the concept and then stall before they become the default operating model. The teams doing it well treat decentralisation as an operational redesign rather than a technology purchase — aligning remote elements with the same oversight discipline as a site-based trial. The teams doing it badly simply add apps and confusion on top of an already overloaded coordinator. But even the disciplined adopters hit a ceiling that no amount of good project management dissolves: the ceiling is regulatory and jurisdictional.

Where decentralised designs are executed well, the deltas are striking. The Singapore PROMOTE maternal-health study reported roughly 97 per cent retention — sitting well above the attrition many site-based trials quietly absorb — and decentralised models repeatedly show lower screen-failure rates and fewer missed visits because participation bends around the patient's life rather than the reverse. Inclusivity improves too: the model reaches populations that geography or mobility would otherwise exclude. When the upside is this legible, the question is no longer whether DCTs work, but why a method that demonstrably improves the metrics sponsors are judged on has not become the default.

Three regulators, three philosophies

Nothing illustrates APAC's fragmentation better than placing its leading DCT jurisdictions side by side. Australia, Singapore and China each profess support for patient-centric, technology-enabled research — and each has arrived at a markedly different regulatory posture.

Australia has gone furthest in building decentralisation into national infrastructure. Its Australasian Teletrial Model was created expressly to bring trials "closer to home" for rural and regional patients, and the federally funded Teletrial Programme has been extending that model across the states and territories since 2020. In May 2024 the government committed fresh funding to a National One Stop Shop intended to harmonise and nationalise trial administration — folding notification, approval, safety reporting and good-clinical-practice inspection into a single platform. Australia's adoption of ICH E6(R3), effective from January 2026 with a one-year transition, formally writes decentralised elements into the country's GCP expectations.

Singapore takes a quieter, more pragmatic route. The Health Sciences Authority regulates trials under the Health Products (Clinical Trials) Regulations and the Human Biomedical Research Act, leaning on ICH GCP rather than issuing a separate, prescriptive DCT rulebook. In practice this flexibility has enabled some of the region's most convincing proof points, including the fully decentralised PROMOTE randomised controlled trial with its 97 per cent retention rate, high completion rates for biological-sample collection, and a smaller environmental footprint than its site-based comparator.

China is the most consequential market and the most cautious. Its Center for Drug Evaluation issued the country's first dedicated DCT technical guidance in May 2024 — but deliberately scoped it to rare-disease drug development, a narrowly defined population in which to pilot the model. As of mid-2025, China had still issued no standalone, comprehensive guideline covering all forms of decentralised research. The intent is clear; the perimeter is small.

Place the three together and the patchwork is obvious. One market treats decentralisation as national policy, one as enabling default, one as a tightly fenced pilot. For a sponsor running a multi-country APAC programme, that divergence is not a nuance — it is the difference between one protocol and three sets of assumptions about what "decentralised" is even permitted to mean.

The data that won't travel

If the framework patchwork sets the ceiling, the data layer is where the real friction bites. A decentralised trial, by definition, scatters data collection across homes, local clinics, wearables and apps — and then needs to consolidate that distributed information into a single analysable dataset, often held by a sponsor headquartered on another continent. Across much of APAC, the rules are pulling in precisely the opposite direction: toward localisation, sovereignty and tightly controlled cross-border movement.

China is the sharpest case. Its Personal Information Protection Law (PIPL), in force since late 2021, classifies clinical health and genetic information as sensitive personal data — and, crucially, treats the coded subject identifiers used under good clinical practice as merely de-identified, not anonymised, so the data remains in scope. Layered on top sits the Human Genetic Resources regime, under which the collection, storage, export and international sharing of human genetic material and information require administrative licensing, with such resources framed as strategic national assets.

Under the PIPL, an outbound transfer of personal information must travel one of three pathways: a security assessment led by the Cyberspace Administration of China, certification by an approved body, or a filed standard contract accompanied by a privacy-impact assessment. Sensitive personal data, or personal data above defined volume thresholds, can trigger the most demanding route; the export of human genetic resources information additionally requires national health-authority clearance.

Consider the archetypal case: a multinational sponsor designs a hybrid oncology study with remote symptom monitoring, home phlebotomy and centralised analytics in a hub outside the country. Sites are enthusiastic, patients are eager, the platform is validated. Then legal review surfaces the obstacle. Because the wearable and app data are sensitive personal information, and because coded identifiers leave the dataset in scope, every outbound transfer must clear a formal pathway — and any genetic component drags in a separate licensing regime on top. The remote-monitoring stream that was the protocol's whole point becomes the element that cannot lawfully flow to where the analysis lives. The trial does not fail; it slows, re-scopes and quietly loses the efficiency advantage it was built to capture.

There are signs of pragmatism. China's 2024 provisions on cross-border data flows eased some thresholds and exemptions, a certification route for outbound personal-information transfers took effect at the start of 2026, and a 2026 consultation draft on human-genetic-resources implementation rules has been read as a move toward a more bifurcated, transaction-friendly regime. Singapore, by contrast, offers a comparatively enabling data environment under its Personal Data Protection Act and human-biomedical-research framework — consent-heavy, particularly for human tissue, but predictable and internationally legible.

From pilot to standard: the operational unlock

If frameworks and data rules explain why DCTs stall, the path to scale runs through four practical levers — none of them a single technology, all of them organisational.

First, local expertise, not imported templates. The studies that work, like Singapore's PROMOTE trial, succeed because the decentralised infrastructure — home nursing, local sample logistics, telehealth touchpoints — is built for the local context rather than lifted from a North American playbook. Decentralisation has to subtract burden from sites, not add it.

Second, streamlined, harmonised ethics review. Fragmented, sequential ethics approval across multiple sites and jurisdictions is one of the quietest killers of DCT timelines. Australia's National One Stop Shop — consolidating notification, approval, safety reporting and inspection into one national platform — is the clearest regional template for what streamlining looks like.

Third, demonstrable technology readiness. Regulators across APAC will accept remote data capture, eConsent and wearable-derived endpoints when, and only when, the tools are validated, secure and clinically defensible. eConsent with genuine comprehension checks, audit-ready remote monitoring and traceable data lineage are no longer differentiators; they are the price of admission.

Fourth, a data architecture built for the rules. The most strategic unlock is to design the data layer for sovereignty from the outset — in-country processing, federated or local analytics, and transfer of only permissible outputs — rather than discovering the constraint after enrolment has begun. Federated approaches, bringing computation to the data rather than the data to the computation, are increasingly the answer, but they demand architecture decisions made before enrolment, not after.

Richie Pfeiffer, senior director of patient first digital solutions at Thermo Fisher Scientific (搜索)搜索该公司, reinforces this perspective: "Sponsors see the strongest results when they adopt flexible, fit-for-purpose approaches tailored to individual studies, rather than applying blanketed DCT models across the board." He notes that "when digital health technologies such as ePROs and eDiaries are deployed within a structured framework, including technical build and testing, global provisioning, and ongoing support, they enable more reliable and seamless data capture."

Underneath all four levers sits a workforce question. Hybrid and decentralised models demand clinical-research professionals who can manage both patient care and data beyond the four walls of a site — a capability that is scarce and unevenly distributed across the region. Building that bench is slower than buying a platform, and arguably more decisive: a sophisticated remote-monitoring stack is worthless without coordinators, home-visit nurses and data managers trained to run it to good-clinical-practice standards.

The trajectory across 2024 to 2026 — Australia's consolidation, Singapore's proof points, China's cautious expansion and the first signs of pragmatism on cross-border data — suggests the pieces are edging toward each other rather than apart. The decentralised trial does not need a breakthrough technology to become standard practice in APAC; the enabling tools already exist and have been proven in the field. What it needs is alignment — between regulators, between data regimes, and between sponsors' efficiency ambitions and the operational reality of building local capacity. Alignment is harder than invention, because it depends on institutions moving in concert rather than a single team executing well.